Pulmonary embolism related to amisulpride treatment: a case report

Case Reports in Psychiatry
Maria Skokou, Philippos Gourzis


Venous thromboembolism has been associated with antipsychotic drugs, but the underlying mechanisms are largely unknown. Hypotheses that have been made include body weight gain, sedation, enhanced platelet aggregation, increased levels of antiphospholipid antibodies, hyperhomocysteinemia, whereas hyperprolactinemia has recently attracted attention as a potential contributing factor. The highest risk has been demonstrated for clozapine, olanzapine, and low-potency first-generation antipsychotics; however, presently there is no data for amisulpride. In the present paper we describe a case of pulmonary embolism in a female bipolar patient, receiving treatment with amisulpride, aripiprazole, and paroxetine. Although a contribution of aripiprazole and paroxetine cannot completely be ruled out, the most probable factor underlying the thromboembolic event seems to be hyperprolactinemia, which was caused by amisulpride treatment. Increased plasma levels of prolactin should probably be taken into account during the monitoring of antipsychotic treatment as well as in future research concerning venous thromboembolism in psychiatric settings.


Aug 1, 1987·Biological Psychiatry·G AddonizioS D Roth
Apr 6, 1999·Schizophrenia Research·R G Petty
Feb 14, 2003·Respiration; International Review of Thoracic Diseases·Claus Kroegel, Angelika Reissig
May 2, 2003·Psychosomatics·Muhammad N MomenPeter F Buckley
Jun 20, 2003·Circulation·Frederick A Anderson, Frederick A Spencer
Nov 5, 2003·Psychosomatics·Christian Lachner, Neil B Sandson
Feb 7, 2004·Pharmacoepidemiology and Drug Safety·Lianne ParkinCharlotte Paul
Aug 27, 2004·Circulation Journal : Official Journal of the Japanese Circulation Society·Satoko HamanakaHitoshi Miyaoka
Nov 30, 2004·General Hospital Psychiatry·Asli KurneKazim M Yazici
Jan 12, 2005·The Journal of Clinical Psychiatry·Rajamannar Ramasubbu
Mar 3, 2005·Acta Psychiatrica Scandinavica·S B LaursenN V Olsen
Dec 14, 2005·Archives of Internal Medicine·Rosa LiperotiGiovanni Gambassi
Jun 30, 2007·Clinical and Experimental Pharmacology & Physiology·Stina AxelssonPer A Whiss
Dec 12, 2007·The Journal of Neuropsychiatry and Clinical Neurosciences·Benjamin Kai Pan Woo
Dec 12, 2007·The Journal of Neuropsychiatry and Clinical Neurosciences·Sayed Shahabuddin Hoseini, Shahriar Gharibzadeh
Feb 19, 2008·The Journal of Emergency Medicine·Laurence BorrasCédric Hermans
Aug 16, 2008·International Clinical Psychopharmacology·Anna K JönssonStaffan Hägg
Dec 11, 2008·Psychiatry and Clinical Neurosciences·Radovan MalyAles Urban
Mar 18, 2009·Journal of the American Pharmacists Association : JAPhA·L Douglas RiedJoel R McConkey
Jul 3, 2009·Expert Opinion on Drug Safety·Staffan HäggOlav Spigset
Feb 5, 2010·JACC. Cardiovascular Interventions·Debabrata Mukherjee, David J Moliterno
Jul 2, 2011·Journal of Clinical Psychopharmacology·Murad Atmaca, Osman Mermi
Nov 5, 2011·Pharmacoepidemiology and Drug Safety·Benoit AllenetJean-Luc Bosson
Dec 14, 2011·Current Rheumatology Reports·Jeffrey S Dlott, Robert A S Roubey
Sep 11, 2012·Best Practice & Research. Clinical Haematology·Samuel Z Goldhaber


Jan 28, 2014·The American Journal of Emergency Medicine·Melike Ceyhan Balcı ŞengülMustafa Serinken

Related Concepts

Bipolar Disorder
Platelet Aggregation
Pulmonary Embolism
Antipsychotic Agents

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

Related Papers

Psychiatry and Clinical Neurosciences
Jiri MasopustMartin Vališ
The Journal of Emergency Medicine
Laurence BorrasCédric Hermans
Journal of Clinical Psychopharmacology
Murad Atmaca, Osman Mermi
Pharmacoepidemiology and Drug Safety
Benoit AllenetJean-Luc Bosson
© 2021 Meta ULC. All rights reserved